Please assess the completion status of the following clinical trial:

Trial Title: Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Note: The information listed below is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial, therefore not all inclusion/exclusion criteria are listed.~Key Inclusion Criteria~1. Diagnosis of HoFH by at least 1 of the following genotype or clinical criteria (all patients on LDL apheresis must be diagnosed based on genotype):~   1. Documented homozygous or compound heterozygous mutations in both low-density lipoprotein receptor (LDLR) alleles~  2. Presence of homozygous or compound heterozygous mutations in Apo B, PCSK9 or LDL receptor adaptor protein 1 (LDLRAP1)~  3. Presence of double heterozygous mutations, i.e, mutations on different genes in the LDLR, Apo B or PCSK9 alleles~  4. Untreated TC \>500 mg/dL (12.93 mmol/L) and TG \<300 mg/dL (3.39 mmol/L) AND Both parents with history of TC \>250 mg/dL (6.46 mmol/L) OR cutaneous or tendinous xanthoma before age 10~2. Receiving a stable dose of a statin at the screening visit (documentation if statin ineffective or patient unable to tolerate statin)~3. If undergoing LDL apheresis, must have initiated LDL apheresis at least 3 months prior to screening and must have been on a stable weekly (every 7 days) or every other week (every 14 days) schedule or stable settings for at least 8 weeks~Key Exclusion Criteria:~1. Documented evidence of a null mutation in both LDLR alleles~2. Use of a PCSK9 inhibitor within 10 weeks from screening visit~3. Background medical lipid modifying therapy (LMT) that has not been stable for at least 4 weeks (6 weeks for fibrates, 24 weeks for mipomersen, 12 weeks for maximum tolerated dose of lomitapide) before the screening visit.~4. LDL apheresis schedule/apheresis settings that have not been stable for at least 8 weeks before the screening visit or an apheresis schedule/settings that is not anticipated to be stable over the next 24 weeks.~5. Use of nutraceuticals or over-the-counter (OTC) therapies known to affect lipids, at a dose/amount that has not been stable for at least 4 weeks prior to the screening visit or between the screening and randomization visits.~6. Chronic use of systemic corticosteroids, unless on a stable regimen of 10 mg daily prednisone equivalent or less for at least 6 weeks prior to randomization. Note: topical, intra-articular, nasal, inhaled and ophthalmic steroid therapies are not considered as 'systemic' and are allowed~7. Systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg at the screening visit (1 repeat measurement is allowed).~8. LDL-C level \<70 mg/dL (1.81 mmol/L) at the screening visit~9. History of a myocardial infarction (MI), unstable angina leading to hospitalization, coronary artery bypass graft surgery, percutaneous coronary intervention , uncontrolled cardiac arrhythmia, carotid surgery or stenting, stroke, transient ischemic attack, valve replacement surgery, carotid revascularization, endovascular procedure or surgical intervention for peripheral vascular disease within 3 months prior to the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alirocumab SC Q2W (Type: EXPERIMENTAL): Alirocumab SC every 2 weeks (Q2W) from baseline (day 1) through week 10 during the double-blind treatment period~Starting at week 12, and continuing through week 22, participants will receive open-label alirocumab SC Q2W
- Placebo SC Q2W (Type: EXPERIMENTAL): Matching placebo SC Q2W from baseline through week 10 during the double-blind treatment period~Starting at week 12, and continuing through week 22, participants will receive open-label alirocumab SC Q2W

Based on this trial design, predict the completion outcome and termination type (if applicable).